行情

OTIC

OTIC

Otonomy
NASDAQ

实时行情|Nasdaq Last Sale

1.870
-0.100
-5.08%
已收盘, 16:00 04/01 EDT
开盘
1.930
昨收
1.970
最高
1.940
最低
1.840
成交量
2.97万
成交额
--
52周最高
4.180
52周最低
1.530
市值
5,762.26万
市盈率(TTM)
-1.2858
分时
5日
1月
3月
1年
5年

分析师评级

5位分析师的综合评级

买入

免责声明:分析师观点仅供投资者决策参考,不构成任何买卖投资建议。

目标价格预测

分析师预测OTIC价格均价为7.60,最高价位10.00,最低价为3.000。

EPS

OTIC 新闻

更多
  • 全球避孕套告急!泰国最大生产商达到产能极限
  • 新浪财经 · 46分钟前
  • 油价大涨 伦敦布伦特油价涨幅扩大至近13%
  • 新浪财经 · 55分钟前
  • 美服装巨头PVH的老板戏剧性确诊感染新冠:无症状
  • 新浪财经 · 1小时前
  • 高盛:垃圾债最坏的日子尚未到来 违约势将增加
  • 新浪财经 · 1小时前

所属板块

生物技术和医学研究
-4.52%
制药与医学研究
-2.91%

热门股票

代码
价格
涨跌幅

OTIC 简况

Otonomy, Inc. is a biopharmaceutical company. The Company focuses on the development and commercialization of therapeutics for diseases and disorders of the ear. The Company's product candidates include OTIPRIO, OTO-104 and OTO-311. OTIPRIO is a single-dose, physician-administered antibacterial, which is used for the treatment of pediatric patients with bilateral otitis media with effusion undergoing tympanostomy tube placement (TTP) surgery and is available for commercial purchase. OTO-104 is a sustained-exposure formulation of the steroid dexamethasone in development for the treatment of Meniere's disease and other inner ear conditions. OTO-311 is a sustained-exposure formulation of the N-Methyl-D-Aspartate (NMDA) receptor antagonist gacyclidine in development for the treatment of tinnitus. It also has various other product candidates, which target sensorinerual hearing loss, including age-related hearing loss, also known as presbycusis.
展开

微牛提供Otonomy Inc(NASDAQ-OTIC)的股票价格,实时市场报价,专业分析师评级,深度图表和免费的OTIC股票新闻,以帮助您做出投资决策。